GeneralConnection.com ➔ Dictionary
Dictionary Search

agio

Synonyms

Noun

1. agiotage

2. premium, exchange premium, charge

Usage
Agios Pharmaceuticals (AGIO) Could Be 11% Undervalued Following Its Rare Disease Growth Narrative - simplywall.st
AGIO Forecast — Price Target — Prediction for 2027 - TradingView
Precision Trading with Agios Pharmaceuticals Inc. (AGIO) Risk Zones - Stock Traders Daily
Agios Pharmaceuticals (AGIO) Is Up 10.3% After New Mitapivat Phase 3 Data and Share Filing – Has The Bull Case Changed? - Sahm
A Quick Look at Today's Ratings for Agios Pharmaceuticals(AGIO.US), With a Forecast Between $36 to $54 - Moomoo
Agios (NASDAQ: AGIO) director exercises RSUs and gains new equity awards - Stock Titan
Agios Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AGIO) - TradingView
AGIOS (AGIO) director Maykin Ho exercises RSUs and receives new equity awards - Stock Titan
Agios (NASDAQ: AGIO) director receives new stock options and RSU awards - Stock Titan
Agios Pharmaceuticals (AGIO) director reports new equity awards and RSU vesting - Stock Titan
Agios (NASDAQ: AGIO) director receives new options and RSU awards - Stock Titan
AGIOS (AGIO) director Scadden exercises RSUs and receives new stock option and RSU awards - Stock Titan
Agios (NASDAQ: AGIO) CMO awarded RSUs, hits milestone for performance units - Stock Titan
AGIOS (NASDAQ: AGIO) CFO receives RSUs and milestone-based performance share units - Stock Titan
Agios (NASDAQ: AGIO) grants Viswanadhan 6,000 RSU and performance share units - Stock Titan
Agios (NASDAQ: AGIO) director reports RSU exercise and new equity grants - Stock Titan
Agios (NASDAQ: AGIO) CEO Brian Goff receives 39,000 stock-based awards - Stock Titan
Agios (NASDAQ: AGIO) director receives stock options, RSUs and exercises units - Stock Titan
[Form 4] AGIOS PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Agios (NASDAQ: AGIO) director receives new stock options and RSU awards - Stock Titan
[Form 4] AGIOS PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Air quality in Agios Nikolaos - IQAir
How The Tebapivat Setback Is Reframing The Story For Agios Pharmaceuticals (AGIO) - Yahoo Finance
Assessing Agios Pharmaceuticals (AGIO) Valuation After Recent Share Price Volatility - Yahoo Finance
AGIO halts tebapivat development in myelodysplastic syndromes - MSN
AGIO Stock Surges 35% in Six Months: What's Driving It? - TradingView
Sickle cell patients needed fewer transfusions with Agios pill in Phase 3 - Stock Titan
Why Is Agios Pharmaceuticals (AGIO) Up 8.6% Since Last Earnings Report? - Yahoo Finance
A Look At Agios Pharmaceuticals (AGIO) Valuation After Recent Share Price Momentum - Yahoo Finance
Agios Pharmaceuticals (AGIO) Stock Could Be 22% Undervalued After RISE UP Phase 3 Data - simplywall.st
Agios Pharmaceuticals (AGIO) Is Up 7.4% After Mitapivat RISE UP Data in Sickle Cell Disease - Has The Bull Case Changed? - simplywall.st
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
AGIO Stock Surges 35% in Six Months: What's Driving It? - The Globe and Mail
AGIO: Mitapivat shows durable efficacy in rare hematology, supporting growth and pipeline expansion - TradingView
BofA Reaffirms Buy Rating for Agios Pharmaceuticals (AGIO) - Yahoo Finance
Agios signs $165M deal for blood disorder drug from Korea’s Oscotec that flunked phase 2 study - Fierce Biotech
AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate - Yahoo Finance
Agios Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Viswanadhan Krishnan - Moomoo
$AGIO stock is down 22% today. Here's what we see in our data. - Quiver Quantitative
Agios Pharmaceuticals (AGIO) Is Up 5.4% After Mixed 2025 Results And AQVESME Launch Progress - Yahoo Finance
Rare blood disorder drug deal gives Agios shot at $1B U.S. sales - Stock Titan
Do Upbeat EPS Revisions Before Earnings Quietly Reframe Agios Pharmaceuticals’ (AGIO) Risk‑Reward Profile? - Yahoo Finance
Costco patio swings recalled after reports of injuries from falls - ABC News - Breaking News, Latest News and Videos
Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last? - Yahoo Finance
AGIO's Pyrukynd Gets Approval for Thalassemia in Europe - Yahoo Finance
Costco shoppers need to check their backyards immediately for this recalled patio swing - AL.com
ATTENTION AGIO SHAREHOLDERS: Investors who lost money on Agios Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation - PR Newswire
Agios (NASDAQ: AGIO) director converts 1,976 RSUs, holds 8,049 shares - Stock Titan
Here's Why Agios Pharmaceuticals Crashed 23% Today - Yahoo Finance
Agios Pharmaceuticals Inc (AGIO) Institutional Confidence - TradingKey
Technical Reactions to AGIO Trends in Macro Strategies - Stock Traders Daily
AGIOS (AGIO) director Catherine Owen Adams converts 1,976 RSUs into common stock - Stock Titan
Agios Pharmaceuticals (NASDAQ: AGIO) boosts 2023 stock plan by 2M shares - Stock Titan
TD Cowen Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating - Moomoo
Agios Pharmaceuticals Reports Positive Phase 3 Results for Mitapivat in Sickle Cell Disease, Highlighting Hemoglobin Response and Reduced Transfusion Burden - Quiver Quantitative
Why Did AGIO Stock Surge 14% Today? - Stocktwits
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $40 - Moomoo
$AGIO stock is up 17% today. Here's what we see in our data. - Quiver Quantitative
Here's Why Agios Pharmaceuticals Crashed 23% Today - The Motley Fool
H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Raises Target Price to $54 - Moomoo
Agios Pharmaceuticals licenses global rights to Oscotec's SYK inhibitor cevidoplenib - Proactive financial news
(AGIO) Volatility Zones as Tactical Triggers - Stock Traders Daily
Earnings Preview: Agios Pharmaceuticals (AGIO) Q1 Earnings Expected to Decline - Yahoo Finance
How The Agios Pharmaceuticals (AGIO) Story Is Shifting After Aqvesme Approval And New Targets - Yahoo Finance
Agios Pharmaceuticals stock tumbles 25% after Novo data - Investing.com
Agio Ratings Secures $6 Million to Expand Risk Management Tools for Digital Assets - Business Wire
AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum - Yahoo Finance
J.P. Morgan Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Maintains Target Price $31 - Moomoo
Agios slides after discontinuing development of tebapivat in myelodysplastic syndromes (AGIO) - Yahoo Finance
Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare Hematology - Slideshow (NASDAQ:AGIO) 2026-06-01 - Seeking Alpha
Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026) - Yahoo Finance
Agios Pharmaceuticals (AGIO) Sees Significant Decline in Stock P - GuruFocus
Agios Pharma shares jump as US FDA expands approval for blood disorder drug - Reuters
Agios (AGIO) Q2 2025 Earnings Call Transcript - The Motley Fool
Agios Pharmaceuticals Secures Exclusive Global Rights to Next-Generation SYK Inhibitor Cevidoplenib for Immune Thrombocytopenia Treatment - Quiver Quantitative
Agios presents detailed mitapivat trial results for sickle cell - Investing.com
AGIO Stock Slumps 25% – What’s The Novo Connection? - Stocktwits
Truist Financial Keeps Their Buy Rating on Agios Pharma (AGIO) - The Globe and Mail
Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything - The Motley Fool
How Agios’ Mitapivat sNDA And New SCD Trial Design At Agios Pharmaceuticals (AGIO) Has Changed Its Investment Story - Yahoo Finance
Agios Halts Tebapivat Trials As Sickle Cell Focus Shapes Valuation - simplywall.st
New pill for sickle cell moves to FDA review, aims to cut transfusions - Stock Titan
Agios Pharmaceuticals, Inc. (AGIO) Stock Price Today & Analysis - Gotrade
Agios’ next-gen PK drug fails blood cancer study but sickle cell disease ambitions remain undimmed - Fierce Biotech
Agios Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Availability of AQVESME™ for Thalassemia - Quiver Quantitative
Agios to stop tebapivat in LR-MDS, plans sickle cell data in 2H 2026 - Stock Titan
Agios (AGIO) Q1 2026 Earnings Call Transcript - The Motley Fool
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease - TradingView
Stop using ‘immediately': Costco patio furniture recalled after multiple reports of injuries - NBC 5 Chicago
Agios to drop myelodysplastic syndromes drug (AGIO:NASDAQ) - Seeking Alpha
Agios (AGIO) Q3 2025 Earnings Transcript - The Motley Fool
Agios Pharmaceuticals Inc (AGIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Analysts Are Neutral on Top Healthcare Stocks: Stevanato Group (STVN), Agios Pharma (AGIO) - The Globe and Mail
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer - Yahoo Finance
Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why - Yahoo Finance
Agios Pharmaceuticals Inc (AGIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Digital asset rater Agio Ratings raises $6m from AlbionVC - FinTech Global
This Biotech Just Lost Half Its Value As Its Rival Celebrated - Investor's Business Daily
Agios: Novo's Sickle Cell Win Changes The PK Activator Game (Rating Downgrade) - Seeking Alpha
Leerink reiterates Agios Pharma stock rating amid rival drug data - Investing.com
Foreign Language Equivalents
Foreign Language Equivalents of 'agio'
Language Equivalent   Language Equivalent
French agio    Spanish
Misspellings - Typos
afio,   agip,   agiio,   aguo,   gaio,   agi,   agii,   ago,   aigo,   aggio,   ahio,   aagio,   sgio,   agoi,   agoo,   gio,   agioo,   aio
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z